GeneDx Holdings (WGS) Cost of Revenue (2020 - 2026)

GeneDx Holdings (WGS) has reported Cost of Revenue for 7 consecutive years, with $36.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 13.88% year-over-year to $36.2 million in Q2 2026; TTM through Jun 2026 was $139.2 million, a 17.05% increase from a year earlier, with the FY2025 full-year figure at $129.4 million, up 16.49% from the prior year.
• Cost of Revenue was $36.2 million for Q2 2026 at GeneDx Holdings, up from $34.0 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $77.7 million in Q4 2022 and troughed at $25.0 million in Q1 2024.
• A 5-year average of $38.0 million and a median of $30.9 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 36.51% in 2022 and tumbled 65.67% in 2023, its largest moves.
• Over 5 years, Cost of Revenue stood at $77.7 million in 2022, then plunged by 65.67% to $26.7 million in 2023, then grew by 10.39% to $29.4 million in 2024, then climbed by 24.75% to $36.7 million in 2025, then declined by 1.41% to $36.2 million in 2026.
• The last three Cost of Revenue figures came in at $36.2 million (Q2 2026), $34.0 million (Q1 2026), and $36.7 million (Q4 2025), per Business Quant data.